Spots Global Cancer Trial Database for Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
Official Title: Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
Study ID: NCT01874171
Conditions
Study Description
Brief Summary: Oropharyngeal squamous cell carcinoma (OPSCC) incidence is increasing rapidly in the developed world. This has been attributed to a rise in Human Papillomavirus (HPV) infection. HPV+OPSCC is considered a distinct disease entity, affecting younger patients and has a good prognosis following treatment. Subsequently, patients can live with the considerable side effects for several decades. Radiotherapy and cetuximab (Epidermal Growth Factor Receptor-inhibitor) have demonstrated similar efficacy to 'platin' chemoradiotherapy (current standard treatment containing platinum-based compounds) in head and neck cancer, but is potentially less toxic. Results of this trial will be used to determine the optimum treatment of this debilitating cancer, with the primary aim of decreasing toxicity and improving quality of life for HPV+OPSCC patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St Luke's Hospital, Dublin, , Ireland
Beaumont Hospital, Dublin, , Ireland
VU University Medical Center, Amsterdam, , Netherlands
Aberdeen Royal Infirmary, Aberdeen, , United Kingdom
Royal United Hospital, Bath, , United Kingdom
Clatterbridge Cancer Centre, Bebington, , United Kingdom
Bradford Royal Infirmary, Bradford, , United Kingdom
Bristol Haematology & Oncology Centre, Bristol, , United Kingdom
Velindre Hospital, Cardiff, , United Kingdom
Cheltenham General Hospital, Cheltenham, , United Kingdom
Colchester General Hospital, Colchester, , United Kingdom
Castle Hill Hospital, Cottingham, , United Kingdom
University Hospitals Coventry & Warwickshire, Coventry, , United Kingdom
Royal Derby Hospital, Derby, , United Kingdom
Queen Elizabeth Hospital Birmingham, Edgbaston, , United Kingdom
Western General Hospital, Edinburgh, , United Kingdom
Royal Devon & Exeter Hospital, Exeter, , United Kingdom
Royal Surrey County Hospital, Guildford, , United Kingdom
St James's Institute of Oncology, Leeds, , United Kingdom
Leicester Royal Infirmary, Leicester, , United Kingdom
University College Hospital, London, , United Kingdom
Royal Marsden Hospital, London, , United Kingdom
James Cook University Hospital, Middlesbrough, , United Kingdom
New Cross Hospital, New Cross, , United Kingdom
Northampton General Hospital, Northampton, , United Kingdom
Norfolk & Norwich University Hospital, Norwich, , United Kingdom
Nottingham University Hopsital, Nottingham, , United Kingdom
Glan Clwyd Hospital, Rhyl, , United Kingdom
Weston Park Hospital, Sheffield, , United Kingdom
Royal Shrewsbury Hospital, Shrewsbury, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Singleton Hospital, Swansea, , United Kingdom
Musgrove Park Hospital, Taunton, , United Kingdom
Contact Details
Name: Hisham Mehanna, PhD, BMedSc (hons), FRCS
Affiliation: University of Birmingham
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
